Dementia & Memory Care

Can I Get an Alzheimer's Infusion? Eligibility Steps

Not everyone with Alzheimer's qualifies for infusions. The six steps — diagnosis, biomarker proof, MRI safety check, medicines review, consent, and monitoring.

Prepared with AI assistance and checked against the linked sources. The update date records an editorial revision; it does not certify physician review.

Zaka Ahmed, MD

Vascular Neurologist · 28 October 2026 · 9 min read

Key Takeaways

Not everyone with Alzheimer's qualifies for infusions — and the pathway exists to protect people as much as to select them.

→ Six steps, in order: confirmed mild-stage diagnosis, Alzheimer's biology confirmed by biomarker, MRI safety check, medicines and history review, an unhurried consent conversation, and a monitoring plan.
→ The two gates that matter most: mild stage (mild cognitive impairment or mild dementia) and confirmed amyloid. Without both, infusions are not offered.
→ Every step has a reason: each check exists because trials showed benefit in a defined group — and higher risk outside it.
→ Declining is always an option: at any step, including after starting, you can pause or stop. The rest of your care continues either way.

When Daniel, 70, asked his doctor about an Alzheimer's infusion, he expected a yes-or-no answer. Instead he got a pathway.

First came memory testing and a diagnosis at the mild stage. Then a blood test, confirmed with spinal fluid, showing Alzheimer's biology. Then a brain MRI, a review of his blood thinner, and a long conversation about a gene variant he had never heard of. Each step took time, and each step had a reason. By the final visit, Daniel understood something the headlines had never told him: eligibility is not a hurdle for its own sake. It is how a treatment with modest average benefit and real risks is offered to the people it may help, and kept from people it may harm.

This page walks through those six steps, in order, so you know what to expect — and what each step is for.

What this means

Anti-amyloid infusions are antibodies that help clear amyloid plaques from the brain. Trials showed they may slow decline modestly on average — not cure dementia, and not restore lost memory. Because the benefit is modest and the main risk (ARIA: swelling or small bleeds visible on MRI) is real, treatment is offered to a defined group: people at the mild stage of Alzheimer's disease, with amyloid confirmed by testing, and with safety checks passed.

The pathway below is that selection process. It usually takes several visits over weeks. A "no" at any step is not a judgment — it is the pathway doing its job.

The six steps, in order

Step 1 — Diagnosis confirmed at the mild stage

The clinician confirms, through history, examination, and cognitive testing, that memory and thinking changes fit mild cognitive impairment (MCI) due to Alzheimer's, or mild dementia due to Alzheimer's. "Mild" here means daily life is affected but independence is largely preserved.

Why this gate exists: trials studied people at this stage. Benefit beyond the mild stage has not been shown, and the balance of benefit and risk may be less favorable later.

Step 2 — Alzheimer's biology confirmed

Amyloid must be shown by testing — a blood biomarker such as p-tau217, spinal fluid (lumbar puncture), or an amyloid PET scan. Blood results that are borderline or unclear may need confirmation with spinal fluid or PET, depending on the clinic's protocol.

Why this gate exists: infusions target amyloid. Without amyloid present, there is nothing for the treatment to act on, and the risks would be taken for no plausible benefit.

Step 3 — MRI safety check

A baseline brain MRI is reviewed for anything that raises risk: prior hemorrhage, many microbleeds (tiny old bleeds), superficial siderosis (iron deposits on the brain surface), swelling, tumors, or other structural problems. Some findings pause or rule out treatment.

Why this gate exists: ARIA risk is higher when the brain already shows bleeding-related changes. The baseline scan also gives later safety scans something to compare against.

Step 4 — Medicines and history review

The clinician reviews blood thinners (and what they are for), history of bleeds, seizures, stroke, and other conditions, and discusses APOE — a gene variant that affects Alzheimer's risk and ARIA risk. People with two copies of APOE ε4 face higher ARIA risk, and that is discussed explicitly, not hidden. APOE testing is offered with counseling, and you can ask questions before deciding.

Why this gate exists: some medicines and histories raise the risk of serious bleeding or complications during treatment. Reviewing them first avoids discovering a problem after treatment has started.

Step 5 — The consent conversation

This is an unhurried discussion, not a signature. It covers: what benefit looks like on average (modest slowing, not recovery); the risks (ARIA, infusion reactions, rare serious events); the burden (infusions every two to four weeks, regular MRI scans, regular travel); the alternatives (standard medicines, planning, support); and the right to decline or stop at any time. Family are welcome. Questions are expected — bring a list.

Why this gate exists: a treatment like this should never start on the basis of a headline. Consent means understanding the trade-off well enough to own the decision either way.

Step 6 — Infusion and monitoring plan

Only after the first five steps: infusions are scheduled at an infusion center, safety MRI scans are booked at set intervals, and a clear contact route is agreed — who to call, day or night, if new symptoms appear. The plan also states, in advance, what would lead to pausing or stopping: ARIA on a scan, advancing beyond the mild stage, a new medical problem, or personal choice.

Why this gate exists: monitoring is part of the treatment, not an optional extra. The scheduled scans are how ARIA is usually caught before it causes symptoms.

What to expect in clinic — a checklist

Visits: several appointments over weeks — diagnosis, biomarker testing, MRI, consent — before any infusion.
Bring: a full medicine list (including blood thinners), prior scans and test results, a family member, and your questions.
Decisions you make: whether to have APOE testing, whether to proceed after the consent conversation, and — at any point — whether to pause or stop.
Paperwork: coverage verification with your health plan before starting, so costs are reviewed in advance. Prices and coverage rules change, so this page does not quote figures.

Symptoms to report — and when to call

During treatment, contact the clinic promptly for any of the following, and seek urgent care (or call 911) if they are severe or sudden:

New or worsening headache, especially if severe or unlike your usual headaches.
New confusion, dizziness, or difficulty thinking clearly.
Vision change, including blurred vision or loss of part of your visual field.
Weakness, numbness, slurred speech, or any stroke-like symptom — call 911.
Fever, chills, rash, or flushing during or after an infusion visit.
Any fall, head injury, or new need for a blood thinner — tell the infusion team before the next visit.

Do not wait for the next scheduled scan to report symptoms. Scans catch most ARIA before symptoms appear, but symptoms between scans deserve a prompt call, not patience.

If the answer is no

A "no" at any step can be disappointing, especially after hoping for a new treatment. It may help to know what a "no" does not mean: it does not mean nothing can be done. Standard Alzheimer's medicines, safety and driving planning, routines, activity, caregiver support, and regular follow-up all continue — and for many people, that plan is the right one. Some "no" answers are also temporary: a borderline biomarker can be rechecked, a medicine can be reviewed, and a decision can be revisited if circumstances change. Ask the clinician which kind of "no" yours is, and what would need to change.

For clinicians

Selection criteria (summary). MCI due to Alzheimer's or mild Alzheimer's dementia by clinical assessment; amyloid pathology confirmed (CSF Aβ42/40 and/or p-tau, amyloid PET, or validated plasma biomarker with confirmatory testing per protocol); baseline MRI within the required window reviewed for hemorrhage, microbleed burden, siderosis, and other exclusions; anticoagulation and comorbidity review; APOE discussion/testing per protocol with explicit counseling for ε4 homozygotes (substantially higher ARIA risk); documented consent covering modest average benefit, ARIA risk, burden, and alternatives; surveillance MRI schedule booked.

Referral workflow. Referring clinician sends: clinical summary and cognitive scores, medicine list (flag anticoagulants/antiplatelets), prior imaging, and prior biomarker results if any. The infusion center confirms: diagnosis stage, biomarker status, MRI safety, and consent — and copies the referring clinician on the decision and the monitoring plan at each step. Target: communication back to the referrer at referral receipt, at decision, and at any treatment change.

Monitoring. Surveillance MRIs at protocol intervals per the agent's labeling; urgent evaluation for new headache, confusion, visual change, or focal symptoms between scans; dose interruption or discontinuation for ARIA per labeling; re-discussion of benefit–risk if dementia advances beyond the mild stage.

References. van Dyck CH, et al. Lecanemab in early Alzheimer's disease (Clarity AD). New England Journal of Medicine, 2023 · Sims JR, et al. Donanemab in early symptomatic Alzheimer disease (TRAILBLAZER-ALZ 2). JAMA, 2023 · Jack CR Jr, et al. Revised criteria for diagnosis and staging of Alzheimer's disease (NIA-AA). Alzheimer's & Dementia, 2024.

Frequently asked questions

How long does the pathway take?

Usually several visits over weeks — diagnosis, biomarker testing, MRI, and a consent visit — before any infusion. The pace depends on test availability and results.

Can I skip the MRI safety check?

No. The baseline MRI is required: it screens for risks and gives later safety scans a comparison. Treatment does not start without it.

Do I have to have APOE testing?

APOE discussion is part of the pathway because it affects ARIA risk, but testing itself is a decision made with counseling. Ask the clinician what it would change for you.

What if I take a blood thinner?

Tell the team early. Some blood thinners affect eligibility or need review; never stop one on your own. The team weighs your clotting risk against infusion risk with you.

Can I change my mind after starting?

Yes — at any time, for any reason. Stopping rules are agreed before starting, and stopping is always an option.

Does coverage get checked before I start?

Yes. The clinic verifies coverage with your health plan and reviews costs with you before the first infusion, so there are no surprises.

Takeaways

Eligibility is a six-step pathway — mild-stage diagnosis, biomarker proof, MRI safety check, medicines review, consent, and monitoring — and each step exists for a safety or evidence reason.
The two gates that matter most are mild stage and confirmed amyloid; without both, infusions are not offered.
A "no" — or a decision to decline — is a legitimate outcome, and full care continues either way.

This article is for education only and is not medical advice. It does not diagnose any individual person or recommend treatment for any individual. If sudden weakness, slurred speech, severe headache, or vision change occurs, call 911 immediately.

When to call us: book a memory assessment if memory change is noticed by you or family, if it affects daily life, or if it is getting worse. During infusion treatment, call promptly for new headache, confusion, dizziness, vision change, or anything unusual after a visit — do not wait for the next scan.